BioLabShare, Inc.’s Post

📣 Funding Biotech Innovation and Scaling Up Join our panel of #BiotechLeaders as they discuss: · How are companies using emerging technologies to give them an edge on innovation and accelerate pipelines? · As the dealmaking landscape shifts, how are companies coming up with new ways to prove value to investors who fund innovation? ·  What challenges do biotech CEOs face in negotiating partnerships? ·  How can companies scale up in order to deliver treatments to patients and returns to investors? 🎙 Hear from: ·  Ellen Donnelly, CEO, Abliva AB ·  Ann Belien, PhD, CEO & Founder, Rejuvenate Biomed ·  Matt Britz, CEO, AffyImmune Therapeutics ·  Daniel Passeri, CEO, Cue Biopharma ·  Rachel Ravens, CEO, 42Genetics Find out more: https://lnkd.in/eGgg9a2b #LSXWorld #Biotech 

🌟 Advanced Therapies Week Highlight: Launch of Charles River's Global Biotech Incubator Program 🌟 Join Kerstin Dolph, Senior VP of Manufacturing at Charles River Laboratories, and host Benjamin McLeod from Convey Bio for an exciting introduction to the Charles River Incubator Program (CIP). This pioneering program supports the journey of early-stage biotechnology companies in the development of advanced therapies. The CIP is dedicated to nurturing startups by offering regulatory guidance, quality expertise, personnel training, and access to laboratory facilities, all aimed at enhancing their path to commercial success. Discover how your biotech venture can apply and benefit from this unique opportunity to accelerate growth and innovation. #AdvancedTherapiesWeek #ATW25 #AdvancedTherapies #CharlesRiver #BiotechIncubator

In a new article series, we introduce the Global Hypergrowth Tokyo cohort companies, exploring the groundbreaking technologies each startup is developing to make a positive impact on the world. In our next profile, meet Hokkaido-based NGENIESS Biosciences, a startup that offers a bioconjugation solution for medicinal and research applications, enabling the production of chemically-modified proteins in a single step with the added capability of highly-selective and homogenous N-terminal modification. Learn more about how NGENIESS Biosciences is revolutionizing drug development: https://buff.ly/4gtZLrx #Hypergrowth #Tokyo #NGENIESSBiosciences

Live from #ATW25, Kerstin Dolph discusses the launch of Charles River’s Incubator Program, designed to help early-stage developers overcome this translation hurdle, with scientific advisory services and capabilities to bolster programs from concept to cure. Explore the benefits: https://bit.ly/40tN4qi Learn more about the program: https://bit.ly/4apDxVO

A thought-provoking observation from David Li on Timmerman Report: as R&D execution becomes increasingly commoditized, the real value creation in therapeutics will come from novel scientific innovation. This underscores what successful biotech leaders already know: success demands both breakthrough science AND operational excellence to thrive in today's therapeutic landscape. With platform technologies proliferating and development timelines accelerating, the differentiation gap is widening. The global landscape is evolving rapidly - are we adapting fast enough?

🌟 Join the Lab of Tomorrow 2024 Survey! 🌟 The biotech industry is evolving rapidly, driven by innovation, investment, and collaboration. But what’s the real story behind this progress? 🔬 Help us discover: ✔️ How biotech and pharma labs are modernizing ✔️ Investments shaping lab technology ✔️ Challenges and opportunities in the industry 💡 Who should participate? Biotech and pharma professionals eager to share insights and learn how others operate. 🎉The study is conducted by A4BEE, and we, as Central European BioForum, are proud to be a partner of this initiative! 🤝 📝 Share your perspective and receive the full report 🚀 🌐 https://lnkd.in/dxfaK7Eh

Check out this interview with Tim Van Hauwermeiren, co-founder and CEO of argenx, where he talks about how the biotech develops novel treatments for autoimmune conditions.

In the realm of biotech collaborations, US companies are leveraging assets licensed from Chinese counterparts, fueling substantial investments. I am currently spearheading multiple metabolic disease projects available for out-licensing. Moreover, a diverse array of projects spanning small molecules, large molecules, ADCs, and peptides across various disease domains are at hand, sourced from over 100 Chinese biotech entities for potential out-licensing opportunities. Exciting times ahead! #BiotechCollaborations #OutLicensing

Yesterday Biotechnology Innovation Organization in partnership with Korn Ferry, released "Charting a Path to Inclusive Excellence for Biotechnology Companies". This survey assesses diversity, equity, and inclusion (#DEI) in the biotechnology industry. At the ongoing BIO International Convention, DEI is a prominent theme. Notably, sessions such as "Building and Sustaining an Inclusive Life Sciences Ecosystem" and "DEI Strategies for Startups: Building a Diverse Workforce from the Ground Up" are scheduled to address these issues directly. These sessions offer valuable insights and strategies for organizations aiming to enhance their DEI initiatives. These discussions at #BIO2024 align perfectly with the findings from the BIO & Korn Ferry survey, providing a platform for industry leaders to share best practices and collaborate on fostering a more inclusive biotech sector. For those attending the conference, these sessions present a prime opportunity to engage with DEI experts and bring actionable insights back to their organizations. The continued focus on DEI is crucial for driving innovation and ensuring the biotech industry reflects the diverse communities it serves. Read the full survey: https://bit.ly/4bY9iVI For more details on these sessions, visit the BIO 2024 program: https://bit.ly/3yHJ6QI

We've seen some more successful funding for biotech in the UK over the past week, reflecting ongoing efforts to drive innovation and address key challenges. 👉 Edinburgh-based Cytomos secured £5 million to advance its cell analysis technology, Celledonia™, aiming to enhance production and global reach. https://lnkd.in/epYPq6dk 👉 Trogenix, a University of Edinburgh spin-out, launched with £15 million in seed funding to develop highly selective, one-time tumor treatments. https://lnkd.in/euywdEWa 👉 4BIO Capital became the first UK venture fund certified by Japan's AMED, enabling support for Japanese life science ventures through non-dilutive funding. https://lnkd.in/ex6_BmpX 👉 UK Research and Innovation (UKRI) invested £5.8 million to bolster the UK's engineering biology sector, fostering innovation and economic growth. https://lnkd.in/eKvuF56r 👉 Naturbeads, based in Bath, raised £7.8 million to combat microplastic pollution, developing biodegradable cellulose beads as sustainable alternatives. https://lnkd.in/eDYVzWrb 👉 Nottingham Trent University has launched a £2.3 million accelerator project to speed up the development of rehabilitation technologies. The project will be led from NTU's Medical Technologies Innovation Facility. This initiative aims to bring world-class innovations to market faster, improving outcomes for those requiring rehabilitation. https://lnkd.in/eBgYF9qt #Biotech #LifeSciences #Innovation #Funding #Sustainability #UKBiotech